Legal Opinion
Marcus v. Forest Pharmaceuticals, Inc.
Court of Appeals for the First Circuit
Decided February 20, 2015No. 14-1290PublishedCited by 53 opinions
1Opinion of the Court
KAYATTA, Circuit Judge.
This appeal arises out of á putative class action against Forest Pharmaceuticals, the manufacturer of Lexapro, an antidepressant medication. Plaintiffs claim that Lex-apro’s FDA-approved drug label misleads California consumers by omitting material efficacy information, in violation of California’s Consumer Legal Remedies Act (“CLRA”), Cal. Civ.Code § 1750 et seq., False Advertising Law (“FAL”), Cal. Bus. & Prof.Code § 17500 et seq., and Unfair Competition Law (“UCL”), Cal. Bus. & Prof.Code § 17200 et seq. The district court dismissed these claims, finding them barred…
2Cases cited8 opinions
- English v. General Electric Co.Supreme Court of the United States · 1990
- Wyeth v. LevineSupreme Court of the United States · 2009
- Cel-Tech Communications, Inc. v. Los Angeles Cellular Telephone Co.California Supreme Court · 1999
- Freightliner Corp. v. MyrickSupreme Court of the United States · 1995
- PLIVA, Inc. v. MensingSupreme Court of the United States · 2011
3 more not listed; retrieve them via the Exa API.
3Cited by53 opinions
- Gibbons v. Bristol-Myers Squibb Co.Court of Appeals for the Second Circuit · 2019
- Gustavsen v. Alcon Laboratories, Inc.Court of Appeals for the First Circuit · 2018
- Painters & Allied Trades Dist. Council 82 Health Care Fund v. Forest Pharm., Inc. (In Re Celexa & Lexapro Mktg. & Sales Practices Litig.)Court of Appeals for the First Circuit · 2019
- Kaufman v. CVS Caremark Corp.Court of Appeals for the First Circuit · 2016
- Dolin v. GlaxoSmithKline LLCCourt of Appeals for the Seventh Circuit · 2018
48 more not listed; retrieve them via the Exa API.